Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurgical Innovations Regulatory News (SUN)

Share Price Information for Surgical Innovations (SUN)

Share Price is delayed by 15 minutes
Get Live Data
0.475    0.00 (0.00%)
Bid:
0.45
Ask:
0.50
Spread: 0.05 (11.111%)
Market Cap: £4.43m
SUN Live PriceLast checked at - London Stock Exchange

Intraday Surgical Innovations Share Chart

Trading Update

19 Feb 2013 07:00

RNS Number : 1437Y
Surgical Innovations Group PLC
19 February 2013
 



 

 

 

Surgical Innovations Group plc

("SI" or the "Company")

 

Trading Update

 

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), provides the following trading update for the financial year ended 31 December 2012.

 

SI saw substantially improved trading across both SI Brand and OEM segments in the second half of 2012, driven by increased product demand resulting in contracted orders for delivery in 2012 of £5.6m. This represents an 85% improvement on first half performance; however due to manufacturing capacity constraints at the existing Leeds facility and a delay in US regulatory approval in the final month of the year, £1m of these orders were recognised as revenue in the first week of the financial year ending 31 December 2013.

 

As a consequence total revenue reported for the 12 months to 31 December 2012 is now expected to be £7.6m (FY 2011: £7.6m).

 

Following the strategic decision to promote SI Branded products, which now represent 68% of overall revenues (FY 2011: 62%), gross margins are expected to have improved by three basis points to 50.3% (FY 2011: 47.3%). Adjusted EBITDA for the period is ahead of the previous year at £2.85m (2011: £2.8m).

 

SI ended the year with short term borrowings of £1.4m against bank facilities provided by HSBC of £2.0m.

 

Given the revenue recognition of £1m in January 2013, the current financial year has started well and provides a sound platform for the remainder of the current financial year.

 

The Company will announce its preliminary results for the year ended 31 December 2012 on Tuesday, 9 April 2013.

 

Graham Bowland, Chief Executive Officer, commented: "I am pleased with the strong sales performance that we've achieved in the second half of the year. There is no doubt that the manufacturing capacity constraints we experienced in the final quarter of 2012 justify the need for our proposed new facility part funded by the award of the £5m RGF."

 

- ENDS -

 

Enquiries:

 

Surgical Innovations Group plc

www.sigroupplc.com

Doug Liversidge, Non-Executive Chairman

Tel: +44 (0) 113 230 7597

Graham Bowland, Chief Executive Officer

graham.bowland@surginno.co.uk

 

 

Seymour Pierce Limited

www.seymourpierce.com

Mark Percy (Corporate Finance)

Tel: +44 (0) 20 7107 8000

David Banks (Corporate Broking)

 

 

 

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Lianne Cawthorne

Mob: 07584 391 303 or lianne.cawthorne@walbrookpr.com

 

Notes to Editors:

 

About Surgical Innovations Group plc

 

Surgical Innovations Group plc specialises in the design and manufacture of creative solutions for minimally invasive surgery (MIS) and industrial markets.

 

As well as manufacturing single-use and reusable instruments for the laparoscopic market, the Group has pioneered its flagship Resposable® instrumentation combining both single use and reusable components, ensuring ongoing revenue streams and delivering the optimum procedure performance to cost ratio.

 

Over 120 people are employed at the Group's 32,000 square feet facility in Leeds, with in-house design, plastic injection moulding and manufacturing equipment, producing products to the highest quality standards.

 

The Group's patented products are sold through three main channels:

 

SI brand

Through an established network of distribution partners, Surgical Innovations branded products are sold in major medical markets including North America, Britain, South East Asia, Australasia and the Indian subcontinent.

 

OEM and IP

The Group supplies large medical device companies on an OEM basis, generating both sales and IP royalty fees. Clients include Teleflex Medical, Olympus and CareFusion.

 

Industrial

 

SI's patented segment technology has been applied to the industrial market enabling customers to undertake inspection and maintenance of large-scale equipment, in situ with minimum disassembly and downtime.

 

For more information, see www.sigrouplplc.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLLFLDFLITLIV
Date   Source Headline
27th Jun 20223:15 pmRNSResult of AGM
27th Jun 20227:00 amRNSAGM Trading Statement
25th May 20227:00 amRNSPosting of 2021 Annual Report & Accounts
9th May 202212:41 pmRNSDirector/PDMR Shareholding
23rd Mar 20227:00 amRNSFinal Results
21st Mar 20227:00 amRNSProduct launch in partnership with CMR Surgical
10th Mar 20227:00 amRNSNotice of Annual Results
17th Jan 20227:00 amRNSYear-end Trading Update
15th Nov 20217:00 amRNSChanges to Board Structure & CFO Appointment
10th Nov 20215:43 pmRNSGrant of Options
15th Sep 20217:00 amRNSHalf-year Report
27th Aug 20217:00 amRNSNotice of Interim Results
9th Jul 20212:29 pmRNSDirector/PDMR Shareholding
22nd Jun 20215:26 pmRNSResult of AGM
22nd Jun 20217:00 amRNSAGM Trading Statement
21st Jun 20217:00 amRNSWithdrawal of AGM Resolution
21st May 20217:00 amRNSPosting of Annual Report& Accounts & Notice of AGM
25th Mar 20217:00 amRNSFinal Results
22nd Mar 20217:00 amRNS3-year Exclusive UK distribution agreement
8th Mar 20217:00 amRNSNotice of annual results
15th Feb 20217:00 amRNS5-year USA distribution agreement
9th Feb 20217:00 amRNSLaunch of the Green Surgery Challenge
8th Jan 20217:00 amRNSDistalmotion’s Dexter Robot receives CE Mark
7th Jan 20217:00 amRNSFuture board change
21st Dec 20207:00 amRNSTrading update
17th Dec 20207:00 amRNSUS distribution agreement signed with Adler
7th Dec 20203:00 pmRNSReplacement of Auditor
2nd Dec 20207:00 amRNSProduct launch for Cellis Breast
25th Nov 20207:00 amRNSCentre for Sustainable Healthcare collaboration
25th Sep 202011:50 amRNSHolding(s) in Company
23rd Sep 20205:20 pmRNSHolding(s) in Company
21st Sep 20201:46 pmRNSHolding(s) in Company
18th Sep 20204:08 pmRNSResult of AGM
17th Sep 202012:54 pmRNSResult of Fundraise
17th Sep 20207:01 amRNSProposed Fundraise
8th Sep 20207:00 amRNSHalf-year Report
21st Aug 20207:00 amRNSNotice of results and Change of AGM 2020 Date
10th Aug 20205:57 pmRNSHolding(s) in Company
10th Jun 20207:00 amRNSPostponement of the Annual General Meeting 2020
4th Jun 20204:50 pmRNSDirector/PDMR Shareholding
4th Jun 20207:00 amRNSNHS Sustainability Webinar
28th May 20207:00 amRNSUpdate on trading &extension to banking facilities
31st Mar 20207:00 amRNSFinal Results
27th Mar 20203:05 pmRNSNotice of results and trading update
13th Jan 20207:00 amRNSYear-end Trading Update
11th Nov 20196:09 pmRNSDirector/PDMR Shareholding
7th Nov 20197:00 amRNSDirector/PDMR Shareholding
5th Nov 20192:56 pmRNSDirector/PDMR Shareholding
25th Oct 20193:12 pmRNSDirector/PDMR Shareholding
7th Oct 20194:12 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.